BUTYLATED HYDROXYTOLUENE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 220.0 | 4.3 | 1 | 1 | 20.0 | 0 | 0.6 |
- CAS
- 128370
- UNII
- 1P9D0Z171K
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 77 ZINC catalogs
Known Active Genes
This compound has been observed to have activity at 10μM or less against the following gene(s).
| Name | Description | Classification |
|---|---|---|
| CA2 | Carbonic anhydrase 2 | Enzyme / Enzyme-Other |
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02220673 | 2009-11-01 | Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B) | Phase 1 | Completed |
| NCT02221375 | 2008-06-01 | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers | Phase 1 | Completed |
| NCT00453375 | 2006-10-01 | Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus | Phase 1 | Completed |
| NCT00382629 | 2006-02-01 | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed |
| NCT00103974 | 2004-07-01 | Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis | Phase 1 | Completed |
(Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Intramuscular | Injection | |
| Intravenous | Injection | |
| Intravenous | Powder, For Injection Solution, Lyophilized | |
| Intravenous | Solution, Injection | |
| Iv(infusion) | Injection | |
| Nasal | Spray, Metered | |
| Oral | Solution, Liquid, Concentrate, Oral | |
| Topical | Aerosol | |
| Topical | Cream, Augmented | |
| Topical | Cream, Emulsion, Sustained Release | |
| Topical | Emulsion, Aerosol Foam | |
| Topical | Emulsion, Cream | |
| Topical | Gel | |
| Topical | Lotion | |
| Topical | Shampoo | |
| Topical | Solution | |
| Transdermal | Gel | |
| Vaginal | Emulsion, Cream | |
| Buccal | Gum, Chewing | 0.21MG |
| Iv(infusion) | Powder, For Injection Solution | |
| Oral | Capsule | 0.2MG |
| Oral | Capsule, Soft Gelatin | 0.25MG |
| Oral | Film, Soluble | 0.06MG |
| Oral | Tablet | 0.4MG |
| Oral | Tablet (immed./comp. Release), Film Coated | 0.15MG |
| Oral | Tablet, Coated | |
| Oral | Tablet, Controlled Release | 0.21MG |
| Oral | Tablet, Extended Release | 0.11MG |
| Oral | Tablet, Film Coated | 0.36MG |
| Oral | Tablet, For Suspension | 0.1MG |
| Oral | Tablet, Orally Disintegrating | 0.21MG |
| Oral | Tablet, Sustained Action | 0.17MG |
| Oral | Tablet, Sustained Action, Coated | 0.24MG |
| Rectal | Suppository | 0.21MG |
| Topical | Ointment | |
| Topical | Swab | |
| Vaginal | Suppository | |
| Oral | Solution |